MYC and neoplasm: Furthermore, targeting the MYC paralog-PARP1-DDR axis via concurrent inhibition of BET and PARP1 resulted in synergistic anti-tumor activity in vitro and in vivo against MYC paralog-driven SCLC cells (Figure 8), but not against MYC paralog-independent SCLC cells.